Used primarily in the treatment of osteoporosis, Paget's disease of bone, and bone metastases, this compound helps reduce bone resorption by inhibiting osteoclast activity. It is effective in increasing bone mineral density, thereby lowering the risk of fractures in postmenopausal women and men with osteoporosis. In oncology, it prevents skeletal-related events in patients with cancers that have spread to bone, such as multiple myeloma and advanced solid tumors. Administered intravenously, it provides a potent option for managing hypercalcemia of malignancy by lowering elevated calcium levels in blood. Its strong affinity for bone tissue allows for infrequent dosing, making it suitable for long-term management in chronic conditions.